Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol Neurosurg Psychiatry
    March 2026
  1. LOMBARDI G, Leveraro E, Cipriano E, Sirito T, et al
    Functional and effective connectivity disruptions of the dopaminergic reward circuit in multiple sclerosis patients with depression.
    J Neurol Neurosurg Psychiatry. 2026 Mar 13:jnnp-2025-336798.
    >> Share

  2. RUIZ-ALGUERO M, Zhu F, Amini F, Zhao Y, et al
    Sex-related and age-related differences in healthcare use before multiple sclerosis symptom onset: a matched cohort study.
    J Neurol Neurosurg Psychiatry. 2026 Mar 13:jnnp-2025-338045.
    >> Share

    February 2026
  3. WITT L, Friedmann N, Haben S, Dost-Kovalsky K, et al
    Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.
    J Neurol Neurosurg Psychiatry. 2026 Feb 27:jnnp-2025-338092.
    >> Share

  4. MOSTERT J, Strijbis EM, D'Haeseleer M, Moral E, et al
    Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset.
    J Neurol Neurosurg Psychiatry. 2026;97:229-238.
    >> Share

  5. KACAR S, van Nederpelt DR, Jelgerhuis JR, Coerver EME, et al
    Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2026 Feb 4:jnnp-2025-337779.
    >> Share

    January 2026
  6. KOCH M, Mostert J, Strijbis EM, D'Haeseleer M, et al
    Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2026 Jan 28:jnnp-2025-337940.
    >> Share

  7. KONEN FF, Axhausen F, Wolff S, Muhlenbrock P, et al
    Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.
    J Neurol Neurosurg Psychiatry. 2026 Jan 20:jnnp-2025-337944.
    >> Share

  8. KREFT KL, Mekkes NJ, Uzochukwu E, Loveless S, et al
    Genetic subtypes associated with multiple sclerosis severity and response to treatment.
    J Neurol Neurosurg Psychiatry. 2026 Jan 16:jnnp-2025-337337.
    >> Share

  9. JACQUES K, Race J, Goyne C, Fair A, et al
    Telomere length as a marker of biological age in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2026 Jan 7:jnnp-2025-336736.
    >> Share

    December 2025
  10. TSERIOTIS VS, Arrambide G, Carnero Contentti E, Tur C, et al
    MRI lesion distribution criteria for MS, NMOSD and MOGAD differentiation: a systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2025;97:59-70.
    >> Share

    November 2025
  11. KAPALI A, Daltveit AK, Myhr KM, Bjornevik K, et al
    Vitamin D intake and multiple sclerosis risk in the Norwegian Mother, Father and Child cohort.
    J Neurol Neurosurg Psychiatry. 2025 Nov 28:jnnp-2025-337300.
    >> Share

    October 2025
  12. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Oct 29:jnnp-2025-336513.
    >> Share

  13. MARIOTTINI A, Mazzeo AC, Simonetti E, Boncompagni R, et al
    Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.
    J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-336808.
    >> Share

  14. VON KAPPELGAARD L, Framke E, Vassard D, Pinborg A, et al
    Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark.
    J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-336080.
    >> Share

  15. SAMARA A, Cohen JA
    Autologous haematopoietic stem cell transplantation in multiple sclerosis: where does it fit in the treatment algorithm?
    J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-337492.
    >> Share

  16. PROSPERINI L, Tacchino A, Ruggieri S, Brichetto G, et al
    Home-based EXergames To impRovE cognitive function in MUltiple Sclerosis (EXTREMUS).
    J Neurol Neurosurg Psychiatry. 2025 Oct 1:jnnp-2025-336609.
    >> Share

    September 2025
  17. HEDSTROM AK, Olsson T, Piehl F, Alfredsson L, et al
    Beneficial impact of physical activity on multiple sclerosis disability progression.
    J Neurol Neurosurg Psychiatry. 2025 Sep 23:jnnp-2025-336738.
    >> Share

  18. MOLENAAR S, Scherbeijn S, Bruijstens A, Buijze MSJ, et al
    Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders.
    J Neurol Neurosurg Psychiatry. 2025;96:975-980.
    >> Share

  19. ZHAO Y, Fei L
    Smoking-attributable neurological health loss: age-specific burden and health disparities.
    J Neurol Neurosurg Psychiatry. 2025;96:937-946.
    >> Share

  20. ELLENBERGER D, Flachenecker P, Haas J, Hellwig K, et al
    Paediatric-onset multiple sclerosis: demographics, symptoms and disease progression.
    J Neurol Neurosurg Psychiatry. 2025 Sep 8:jnnp-2025-336680.
    >> Share

  21. MURARO PA, Kazmi M, De Matteis E, Brittain G, et al
    Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.
    J Neurol Neurosurg Psychiatry. 2025 Sep 5:jnnp-2025-336755.
    >> Share

  22. GAVOILLE A, Nourredine M, Rollot F, Casey R, et al
    Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Sep 4:jnnp-2025-336762.
    >> Share

  23. CALVI A, Vivo Pascual F, Solana E, Lopez-Soley E, et al
    Diffusivity anisotropy signature of the slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Sep 1:jnnp-2025-335884.
    >> Share

    July 2025
  24. ROBERTS JI, Sharmin S, Horakova D, Kubala Havrdova E, et al
    Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
    J Neurol Neurosurg Psychiatry. 2025 Jul 28:jnnp-2025-336343.
    >> Share

  25. SYC-MAZUREK SB, Cacciaguerra L, Tajfirouz DA, Redenbaugh V, et al
    MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Jul 20:jnnp-2025-336684.
    >> Share

  26. BOCCIA VD, Leveraro E, Cipriano E, Lapucci C, et al
    Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions.
    J Neurol Neurosurg Psychiatry. 2025;96:807-813.
    >> Share

  27. TAN H, Deng X, ZhangBao J, Zhou L, et al
    KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.
    J Neurol Neurosurg Psychiatry. 2025 Jul 11:jnnp-2025-335953.
    >> Share

    June 2025
  28. BAKER D, Alfredsson L, Hedstrom AK, Schmierer K, et al
    Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility.
    J Neurol Neurosurg Psychiatry. 2025 Jun 27:jnnp-2024-335304.
    >> Share

  29. ZANGHI A, Copetti M, Avolio C, Paolicelli D, et al
    Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.
    J Neurol Neurosurg Psychiatry. 2025 Jun 15:jnnp-2025-335958.
    >> Share

  30. ABDELHAK A, Bachhuber F, Ning K, Benkert P, et al
    Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
    J Neurol Neurosurg Psychiatry. 2025 Jun 12:jnnp-2025-335831.
    >> Share

  31. YAMOUT B, Alroughani R, Mohamed SFA, Al-Mahdawi AM, et al
    Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study.
    J Neurol Neurosurg Psychiatry. 2025 Jun 1:jnnp-2024-335704.
    >> Share

    May 2025
  32. SALTER A, Lancia S, Kowalec K, Fitzgerald K, et al
    Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 May 24:jnnp-2024-335710.
    >> Share

  33. AHOLA V, Saraste M, Nylund M, Matilainen M, et al
    Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 May 16:jnnp-2025-336063.
    >> Share

  34. LORSCHEIDER J, Signori A, Subramaniam S, Benkert P, et al
    Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
    J Neurol Neurosurg Psychiatry. 2025;96:606-615.
    >> Share

    April 2025
  35. RUSKA B, Adamec I, Crnosija L, Gabelic T, et al
    Evolution of autonomic nervous system abnormalities in multiple sclerosis: a 6-year follow-up.
    J Neurol Neurosurg Psychiatry. 2025 Apr 24:jnnp-2024-335376.
    >> Share

  36. ZICCARDI S, Guandalini M, Crescenzo F, Martinelli L, et al
    Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course.
    J Neurol Neurosurg Psychiatry. 2025 Apr 23:jnnp-2025-335925.
    >> Share

  37. YAM C, Brownlee WJ, Prados Carrasco F, Toosy A, et al
    Investigating colour vision and its structural correlates 15 years following a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2025;96:435-442.
    >> Share

    March 2025
  38. SHIPLEY J, Beadnall H, Butzkueven H, van der Walt A, et al
    Impact of pregnancy on the maternal brain in health and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335319.
    >> Share

  39. MANOUCHEHRINIA A, Zhu F, Hillert J, McKay K, et al
    Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset - a matched cohort study.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335279.
    >> Share

  40. GELISSEN LMY, Toorop AA, Schipper PM, Hoitsma E, et al
    Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335761.
    >> Share

  41. GIORDANO A, Giliberti A, Clarelli F, Misra K, et al
    Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 13:jnnp-2024-335547.
    >> Share

  42. DZAU W, Roos I, Kalincik T
    Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335495.
    >> Share

  43. WINTER P, Axhausen F, Wolff S, Willison AG, et al
    Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335673.
    >> Share

  44. NOUI Y, Zjukovskaja C, Silfverberg T, Ljungman P, et al
    Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335512.
    >> Share

    February 2025
  45. JOHANSSON E, Guo J, Wu J, Olsson T, et al
    Impact of fish consumption on disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 25:jnnp-2024-335200.
    >> Share

  46. LAUERER M, Wiltgen T, Bruckner C, Engl C, et al
    Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.
    J Neurol Neurosurg Psychiatry. 2025 Feb 17:jnnp-2024-335037.
    >> Share

  47. GUO J, Olsson T, Hillert J, Alfredsson L, et al
    Lifestyle factors associated with benign multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 13:jnnp-2024-335464.
    >> Share

    January 2025
  48. GOMBOLAY G, Johnson L, King R, Hebert M, et al
    Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition.
    J Neurol Neurosurg Psychiatry. 2025 Jan 23:jnnp-2024-335175.
    >> Share

    December 2024
  49. DE ANGELIS F, Cameron JR, Eshaghi A, Parker R, et al
    Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
    J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801.
    >> Share

  50. DE MOL CL, Lamballais S, Muetzel R, Duijts L, et al
    Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population.
    J Neurol Neurosurg Psychiatry. 2024 Dec 10:jnnp-2024-335053.
    >> Share

  51. JEANTIN L, Bensa-Koscher C, Deschamps R, Gout O, et al
    Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning.
    J Neurol Neurosurg Psychiatry. 2024 Dec 4:jnnp-2024-334629.
    >> Share

    October 2024
  52. RUBIN M, Preziosa P, Margoni M, Meani A, et al
    Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Oct 10:jnnp-2024-334913.
    >> Share

    September 2024
  53. SCHOEPS VA, Bhargava P, Virupakshaiah A, Ladakis DC, et al
    Distinct plasma lipids predict axonal injury and multiple sclerosis activity.
    J Neurol Neurosurg Psychiatry. 2024 Sep 12:jnnp-2024-333652.
    >> Share

  54. ZARGHAMI A, Hussain MA, van der Mei I, Simpson-Yap S, et al
    Long-term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort.
    J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-333632.
    >> Share

    August 2024
  55. GHEZZI L, Tosti V, Shi L, Cantoni C, et al
    Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Aug 13:jnnp-2024-333465.
    >> Share

    July 2024
  56. ANANTHAVARATHAN P, Sahi N, Chung K, Haider L, et al
    The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 22:jnnp-2024-333917.
    >> Share

  57. MIN YG, Moon Y, Kwon YN, Lee BJ, et al
    Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.
    J Neurol Neurosurg Psychiatry. 2024;95:753-760.
    >> Share

  58. GIORDANO A, Clarelli F, Pignolet B, Mascia E, et al
    Vitamin D affects the risk of disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 14:jnnp-2024-334062.
    >> Share

  59. GOODIN DS
    Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms.
    J Neurol Neurosurg Psychiatry. 2024 Jul 2:jnnp-2023-333296.
    >> Share

    June 2024
  60. SHI L, Ghezzi L, Fenoglio C, Pietroboni AM, et al
    CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jun 6:jnnp-2024-333774.
    >> Share

  61. DAS J, Mallawaarachchi G, Grimshaw J, Jackson T, et al
    Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study.
    J Neurol Neurosurg Psychiatry. 2024 Jun 5:jnnp-2024-333338.
    >> Share

    May 2024
  62. NICHOLAS R, Tallantyre EC, Witts J, Marrie RA, et al
    Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
    J Neurol Neurosurg Psychiatry. 2024 May 23:jnnp-2024-333532.
    >> Share

  63. ROCCA MA, Valsasina P, Romano F, Tedone N, et al
    Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol Neurosurg Psychiatry. 2024 May 16:jnnp-2024-333460.
    >> Share

  64. ENGLUND S, Frisell T, Qu Y, Gandhi K, et al
    Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2024-333595.
    >> Share

  65. VIRTANEN S, Piehl F, Frisell T
    Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2023-333206.
    >> Share

  66. THIEL S, Litvin N, Haben S, Gold R, et al
    Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy.
    J Neurol Neurosurg Psychiatry. 2024;95:561-570.
    >> Share

  67. MAAROUF A, Stellmann JP, Rico A, Boutiere C, et al
    Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 May 6:jnnp-2024-333597.
    >> Share

    April 2024
  68. ABDEL-MANNAN O, Champsas D, Tur C, Lee V, et al
    Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course.
    J Neurol Neurosurg Psychiatry. 2024;95:426-433.
    >> Share

  69. MAHLER MR, Magyari M, Pontieri L, Elberling F, et al
    Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265.
    >> Share

  70. DEKEYSER C, Hautekeete M, Cambron M, Van Pesch V, et al
    Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307.
    >> Share

    March 2024
  71. VERSTEGEN NJM, Hagen RR, Kreher C, Kuijper LH, et al
    T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224.
    >> Share

  72. KALINCIK T, Sharmin S, Roos I, Massey J, et al
    Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790.
    >> Share

  73. JONS D, Grut V, Bergstrom T, Zetterberg H, et al
    Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
    J Neurol Neurosurg Psychiatry. 2024;95:325-332.
    >> Share

  74. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
    >> Share

  75. JING J, Zhang Z, Su L, Gao C, et al
    Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
    >> Share

    February 2024
  76. POZZILLI V, Haggiag S, Di Filippo M, Capone F, et al
    Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2023-332996.
    >> Share

  77. IOANNIDIS JP
    Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2024-333329.
    >> Share

    January 2024
  78. SIGNORI A, Ponzano M, Kalincik T, Ozakbas S, et al
    Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
    J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603.
    >> Share

  79. JOHANSSON E, Alfredsson L, Strid P, Kockum I, et al
    Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals.
    J Neurol Neurosurg Psychiatry. 2024 Jan 11:jnnp-2023-332643.
    >> Share

    December 2023
  80. ELSBERND P, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Cerebral enhancement in MOG antibody-associated disease.
    J Neurol Neurosurg Psychiatry. 2023;95:14-18.
    >> Share

  81. ZIVADINOV R, Pei J, Clayton D, Goldman DE, et al
    Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
    J Neurol Neurosurg Psychiatry. 2023 Dec 6:jnnp-2023-332573.
    >> Share

    November 2023
  82. ALBA-ARBALAT S, Solana E, Lopez-Soley E, Camos-Carreras A, et al
    Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 21:jnnp-2023-332332.
    >> Share

  83. KOCH M
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332758.
    >> Share

  84. TOOROP AA, van Lierop ZY, Gelissen LM, Hoitsma E, et al
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332119.
    >> Share

  85. FISSOLO N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, et al
    Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 8:jnnp-2023-332251.
    >> Share

  86. PALMER AJ, Zhao T, Taylor BV, van der Mei I, et al
    Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
    J Neurol Neurosurg Psychiatry. 2023 Nov 2:jnnp-2023-332161.
    >> Share

    October 2023
  87. CAMPBELL JA, van der Mei I, Taylor BV, Palmer AJ, et al
    Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
    J Neurol Neurosurg Psychiatry. 2023 Oct 26:jnnp-2022-330755.
    >> Share

  88. MONTINI F, Nozzolillo A, Tedone N, Mistri D, et al
    COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
    J Neurol Neurosurg Psychiatry. 2023 Oct 19:jnnp-2023-332073.
    >> Share

  89. MAIWORM M, Hamid C, Wagner M, Noth U, et al
    Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS.
    J Neurol Neurosurg Psychiatry. 2023;94:786-791.
    >> Share

    September 2023
  90. RUGGIERI S, Prosperini L, Al-Araji S, Annovazzi PO, et al
    Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 29:jnnp-2023-331920.
    >> Share

  91. SILFVERBERG T, Zjukovskaja C, Ljungman P, Nahimi A, et al
    Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 25:jnnp-2023-331864.
    >> Share

  92. YUSUF FLA, Asaf A, Marrie RA, Li P, et al
    Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population.
    J Neurol Neurosurg Psychiatry. 2023 Sep 21:jnnp-2023-331991.
    >> Share

    August 2023
  93. GAY MC, Cassedanne F, Barbot F, Vaugier I, et al
    Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.
    J Neurol Neurosurg Psychiatry. 2023 Aug 30:jnnp-2023-331537.
    >> Share

  94. LONGINETTI E, Englund S, Burman J, Fink K, et al
    Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
    J Neurol Neurosurg Psychiatry. 2023 Aug 9:jnnp-2023-331784.
    >> Share

  95. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Perez-Rios M, Ruano-Ravina A, et al
    Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials.
    J Neurol Neurosurg Psychiatry. 2023 Aug 4:jnnp-2023-331733.
    >> Share

  96. HABEN S, Ciplea AI, Tokic M, Timmesfeld N, et al
    Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Aug 3:jnnp-2023-331525.
    >> Share

    July 2023
  97. LAUERER M, McGinnis J, Bussas M, El Husseini M, et al
    Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 26:jnnp-2023-331799.
    >> Share

  98. KAPALI A, Daltveit AK, Myhr KM, Bjornevik K, et al
    Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study.
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331241.
    >> Share

  99. JEANTIN L, Abdi B, Soulie C, Sterlin D, et al
    Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331770.
    >> Share

  100. MOROZUMI T, Preziosa P, Meani A, Albergoni M, et al
    Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2023-331482.
    >> Share

  101. COLATO E, Prados F, Stutters J, Bianchi A, et al
    Networks of microstructural damage predict disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2022-330203.
    >> Share

  102. ROSENKRANZ SC, Gutmann L, Has Silemek AC, Dorr M, et al
    Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 11:jnnp-2023-331183.
    >> Share

  103. DZAU W, Sharmin S, Patti F, Izquierdo G, et al
    Risk of secondary progressive multiple sclerosis after early worsening of disability.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748.
    >> Share

  104. DIOUF I, Malpas CB, Sharmin S, Roos I, et al
    Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499.
    >> Share

    June 2023
  105. MARTINEZ-HERAS E, Solana E, Vivo F, Lopez-Soley E, et al
    Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes.
    J Neurol Neurosurg Psychiatry. 2023 Jun 15:jnnp-2023-331531.
    >> Share

  106. HOUZEN H, Kano T, Kondo K, Takahashi T, et al
    Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    J Neurol Neurosurg Psychiatry. 2023;94:494-495.
    >> Share

    May 2023
  107. STRIJBIS EM, Coerver E, Mostert J, van Kempen ZLE, et al
    Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 12:jnnp-2022-330887.
    >> Share

  108. SARASTE M, Matilainen M, Vuorimaa A, Laaksonen S, et al
    Association of serum neurofilament light with microglial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 2:jnnp-2023-331051.
    >> Share

    April 2023
  109. NOVAK F, Bajwa HM, Coia JE, Nilsson AC, et al
    Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
    J Neurol Neurosurg Psychiatry. 2023 Apr 25:jnnp-2022-330757.
    >> Share

  110. LEPPERT D, Watanabe M, Schaedelin S, Piehl F, et al
    Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 19:jnnp-2022-330796.
    >> Share

  111. HARDING-FORRESTER S, Roos I, Nguyen AL, Malpas CB, et al
    Disability accrual in primary and secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726.
    >> Share

  112. MOCCIA M, Affinito G, Fumo MG, Giordana R, et al
    Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330883.
    >> Share

    March 2023
  113. WU J, Olsson T, Hillert J, Alfredsson L, et al
    Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
    J Neurol Neurosurg Psychiatry. 2023 Mar 31:jnnp-2022-330848.
    >> Share

  114. MARGONI M, Preziosa P, Storelli L, Gueye M, et al
    Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients.
    J Neurol Neurosurg Psychiatry. 2023 Mar 29:jnnp-2022-331027.
    >> Share

  115. RIVERO-DE-AGUILAR A, Perez-Rios M, Ruano-Ravina A, Candal-Pedreira C, et al
    Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov.
    J Neurol Neurosurg Psychiatry. 2023 Mar 28:jnnp-2023-331132.
    >> Share

  116. LEADBETTER R, MacAskill M, Myall DJ, Taylor BV, et al
    Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
    J Neurol Neurosurg Psychiatry. 2023 Mar 7:jnnp-2022-330582.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016